Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QPCT | Q16769 | 7/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | SOD1 | P00441 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | PRKCI | P41743 | 1/20 | 0.42 |
| ▸ | TBXAS1 | P24557 | 3/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.40 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18457438 | 0.81 | QPCT (0.56) | QPCTSOD1TBXAS1CYP19A1CACNA1B | |
| SCHEMBL25039563 | 0.79 | KMT2A (0.58) | QPCTKMT2ASOD1PRKCINPC1 | |
| SCHEMBL77450 | 0.75 | QPCT (1.00) | QPCTKMT2AMAOAMAOB | |
| SCHEMBL20280709 | 0.75 | QPCT (0.52) | QPCTKMT2ASOD1NPC1RAB9A | |
| SCHEMBL10852247 | 0.75 | TBXAS1 (0.62) | QPCTKMT2ATBXAS1NPC1 | |
| SCHEMBL27827572 | 0.75 | QPCT (0.49) | QPCTKMT2APRKCITBXAS1ALOX15 | |
| SCHEMBL8447325 | 0.74 | QPCT (0.58) | QPCTKMT2ASOD1PRKCITBXAS1 | |
| Hydrochloric Acid SCHEMBL10852436 | 0.74 | TBXAS1 (0.63) | QPCTKMT2ATBXAS1NPC1 | |
| SCHEMBL13164564 | 0.74 | CYP1A2 (0.56) | QPCTKMT2ANPC1RAB9AATM | |
| SCHEMBL4173548 | 0.72 | QPCT (0.56) | QPCTKMT2ATBXAS1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090023735-A1 | Sulphonamide Derivatives | BIOTIE THERAPIES CORP. (FI) | 2009-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023735-A1 | Sulphonamide Derivatives | HCAR1, ADGRE5, ALK | QPCT 3071/4885KMT2A 2643/4885SOD1 3535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.